医学
前列腺癌
肿瘤科
队列
内科学
阶段(地层学)
回顾性队列研究
前列腺
总体生存率
疾病
人口
局限性疾病
多参数磁共振成像
癌症
队列研究
全身疗法
介绍(产科)
肿瘤分期
靶向治疗
T级
放射科
前列腺癌的治疗
外照射放疗
挽救疗法
放射治疗
作者
Kim van der Velden,D. Bosch,Z. Vassilev,Andries Marinus Bergman,A.C.M. van den Bergh,Maarten Johannes van der Doelen,Alfons J.M. van den Eertwegh,Jules Lavalaye,R. Jeroen A. van Moorselaar,Diederink M. Somford,Metin Tascilar,A. Raval,C.A. Uyl-de Groot,Malou C. P. Kuppen,I.M. van Oort
标识
DOI:10.1007/s00259-026-08050-7
摘要
PURPOSE: Since 2019, EAU guidelines recommend PSMA-PET/CT for staging high-risk prostate cancer. However, real-world data on its uptake and association with disease characteristics and outcomes in metastatic castration-sensitive prostate cancer (mCSPC) remains limited. We evaluated real-world PSMA-PET/CT use versus conventional imaging (CI). METHODS: This retrospective study included 3,644 mCSPC patients (2016-2021) from 19 hospitals in the Dutch CAPRI-3 registry. Staging within 90 days of diagnosis was classified as CI-only (CT, bone scintigraphy, and/or MRI) or PSMA-PET (± CI). RESULTS: Most patients were staged with CI-only (63%), but PSMA-PET use rose from 8% in 2016 to 62% in 2021. PSMA-PET-staged patients were younger (72 vs. 76 years) and had significantly lower tumour burden (27% vs. 45% high-volume), more nodal-only disease, and were more likely to have metachronous presentation (29% vs. 22%, all P < 0.001). In the PSMA-PET group, 42% received ADT plus targeted therapy and 23% ADT monotherapy (vs. 45% ADT monotherapy in CI-only). Median overall survival was significantly longer in the PSMA-PET cohort (78.3 vs. 40.0 months). CONCLUSION: There has been an increasing trend toward the use of PSMA PET/CT for staging mCSPC in recent years, identifying a population with more favourable disease characteristics and a more favourable prognosis. This shift in patient characteristics, driven by stage migration (the Will Rogers phenomenon), influences clinical management by enabling more refined patient selection for conservative or targeted therapies. Consequently, accounting for lead-time and selection bias is essential when comparing survival outcomes in the PSMA PET/CT era.
科研通智能强力驱动
Strongly Powered by AbleSci AI